Literature DB >> 23940435

In vitro effects of L-carnitine on coronary artery bypass grafts.

Orkut Güçlü1, Volkan Yüksel, Serhat Hüseyin, Turan Ege, Suat Canbaz, Mutasim Süngün.   

Abstract

BACKGROUND: The gold standard treatment for multivessel coronary revascularization is coronary artery bypass grafting. The internal mammary artery and saphenous vein grafts are the conduits most frequently used for these operations. Spasm of arterial and venous grafts is a significant problem during the operation.
OBJECTIVES: To evaluate the acute in vitro effects of L-carnitine on internal mammary artery and saphenous vein grafts using a tissue bath.
METHODS: Ten consecutive patients who underwent elective coronary artery bypass grafting were enrolled in the present study (nine men, one woman; mean [± SD] age 62±9.1 years). Samples from left internal mammary artery and saphenous vein grafts were collected from each patient. Submaximal smooth muscle contraction was achieved by adding 1 μM phenylephrine, and L-carnitine was then added to the solution. The concentration-response curves of the vasodilation response were obtained.
RESULTS: In the internal mammary graft samples, the vasodilation response to L-carnitine was 64.3±11.1% at a concentration of 5 mM. In the saphenous vein graft samples, the vasodilation response to L-carnitine was 41.5±11.4% at a concentration of 5 mM. There was a statistically significant difference (P<0.001) between the response of the internal mammary artery and saphenous vein grafts in the in vitro tissue bath system.
CONCLUSIONS: These results indicate that L-carnitine is a potential vasodilatory drug for internal mammary artery and saphenous vein grafts.

Entities:  

Keywords:  Coronary artery bypass; Internal mammary artery; L-carnitine; Saphenous vein

Year:  2013        PMID: 23940435      PMCID: PMC3718590     

Source DB:  PubMed          Journal:  Exp Clin Cardiol        ISSN: 1205-6626


  14 in total

Review 1.  Arterial grafts for coronary artery bypass grafting: biological characteristics, functional classification, and clinical choice.

Authors:  G W He
Journal:  Ann Thorac Surg       Date:  1999-01       Impact factor: 4.330

2.  The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study.

Authors:  L Cacciatore; R Cerio; M Ciarimboli; M Cocozza; V Coto; A D'Alessandro; L D'Alessandro; G Grattarola; L Imparato; M Lingetti
Journal:  Drugs Exp Clin Res       Date:  1991

Review 3.  Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review.

Authors:  Roberto Ferrari; E Merli; G Cicchitelli; D Mele; A Fucili; C Ceconi
Journal:  Ann N Y Acad Sci       Date:  2004-11       Impact factor: 5.691

4.  Propionyl-L-carnitine dilates human subcutaneous arteries through an endothelium-dependent mechanism.

Authors:  M J Cipolla; A Nicoloff; T Rebello; A Amato; J M Porter
Journal:  J Vasc Surg       Date:  1999-06       Impact factor: 4.268

5.  L-carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: different participation of NO and COX-products.

Authors:  Rosario Bueno; Maria Alvarez de Sotomayor; Concepción Perez-Guerrero; Lucia Gomez-Amores; Carmen M Vazquez; M Dolores Herrera
Journal:  Life Sci       Date:  2005-09-09       Impact factor: 5.037

6.  Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage.

Authors:  Lorenzo A Calò; Elisa Pagnin; Paul A Davis; Andrea Semplicini; Raffaella Nicolai; Menotti Calvani; Achille C Pessina
Journal:  Int J Cardiol       Date:  2006-02-08       Impact factor: 4.164

Review 7.  Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass.

Authors:  R Lango; R T Smolenski; M Narkiewicz; J Suchorzewska; W Lysiak-Szydlowska
Journal:  Cardiovasc Res       Date:  2001-07       Impact factor: 10.787

8.  Administration of L-carnitine and mildronate improves endothelial function and decreases mortality in hypertensive Dahl rats.

Authors:  Reinis Vilskersts; Janis Kuka; Baiba Svalbe; Helena Cirule; Edgars Liepinsh; Solveiga Grinberga; Ivars Kalvinsh; Maija Dambrova
Journal:  Pharmacol Rep       Date:  2011       Impact factor: 3.024

9.  Effect of L-carnitine and propionyl-L-carnitine on endothelial function of small mesenteric arteries from SHR.

Authors:  Maria Alvarez de Sotomayor; Rosario Bueno; Concepción Pérez-Guerrero; Maria Dolores Herrera
Journal:  J Vasc Res       Date:  2007-05-04       Impact factor: 1.934

10.  Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study.

Authors:  G Brevetti; M Chiariello; G Ferulano; A Policicchio; E Nevola; A Rossini; T Attisano; G Ambrosio; N Siliprandi; C Angelini
Journal:  Circulation       Date:  1988-04       Impact factor: 29.690

View more
  1 in total

1.  Nifedipine toxicity is exacerbated by acetyl l-carnitine but alleviated by low-dose ketamine in zebrafish in vivo.

Authors:  Bonnie L Robinson; Qiang Gu; Volodymyr Tryndyak; Syed F Ali; Melanie Dumas; Jyotshna Kanungo
Journal:  J Appl Toxicol       Date:  2019-10-09       Impact factor: 3.628

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.